Circrna Synthesis Market: Market Size & Forecast 2026

Circular RNA synthesis encompasses enzymatic and chemical production methods used to manufacture circRNA molecules for academic research, drug discovery, and clinical therapeutic development. The global market is estimated at approximately $207 million in 2025, though commercial research firms report 2025 figures ranging from roughly $187 million to $214 million depending on methodology and scope. Market projections extend to 2030-2035, with forecasts pointing to values between roughly $404 million and $829 million over that horizon, reflecting broad consensus on strong sustained growth.

• •Commercial market size estimates for 2025 range from approximately $187 million to $214 million across major research firms, with a central figure of ~$207 million
• •Long-term projections through 2030-2035 range from ~$404 million to ~$829 million, with most firms projecting 15%-16% CAGR growth
• •No official government statistical agency formally calculates market size; figures are derived independently by commercial research organizations

The COVID-19 pandemic validated mRNA technology at commercial scale, creating momentum and investment capacity that spills over into next-generation RNA modalities like circRNA. CircRNA's inherently closed-loop structure resists exonuclease degradation, enabling longer-lasting protein expression with potentially reduced dosing requirements compared to linear mRNA. Growing biopharmaceutical pipeline activity in gene therapy, protein replacement, and cancer immunotherapy is increasing demand for reliable, scalable circRNA synthesis services and manufacturing technologies.

• •Demonstrated success of mRNA vaccines created investor confidence and manufacturing infrastructure that benefits next-generation RNA platforms
• •CircRNA's nuclease-resistant circular structure enables extended protein expression, potentially reducing dosing frequency and improving therapeutic index
• •Expanding biopharmaceutical pipeline activity in oncology, rare diseases, and protein therapeutics is fueling demand for circRNA manufacturing capabilities

The market is typically segmented by synthesis method, application area, and end-user type, including enzymatic synthesis, chemical synthesis, and in vitro transcription services. Applications span research and development, drug discovery, and clinical-stage therapeutic development. North America currently dominates the regional market, with one analysis projecting a regional CAGR of approximately 14.5% through 2030, supported by a dense biopharmaceutical industry, prominent research institutions, and significant venture capital and corporate investment in RNA-based therapeutics.

• •North America leads the global market, supported by concentration of biopharma companies, research institutions, and RNA-focused venture investment
• •Key service segments include custom circRNA synthesis, plasmid DNA templates, enzymatic kit products, and full-scale manufacturing services
• •Therapeutic applications span protein replacement therapy, cancer vaccines, and gene editing research, each with distinct technical and regulatory requirements

What are the recent trends and outlook?

The circRNA synthesis market is at an early but accelerating stage of commercialization, with growing investment in process optimization, scalable manufacturing, and quality control methodologies suited to regulatory approval pathways. Advances in enzymatic circularization efficiency, reduced immunogenicity through nucleotide modification, and improved delivery formulations are expanding the practical applications of circRNA therapeutics. Over the 2025-2035 forecast horizon, the market is expected to mature as clinical-stage circRNA programs advance through regulatory review and manufacturing processes shift from research-scale to commercial-scale production.

• •Process improvements in enzymatic circularization and modified nucleotide chemistry are reducing manufacturing costs and improving circRNA product consistency
• •Clinical progression of circRNA-based therapeutics through Phase I and Phase II trials would likely accelerate market expansion and attract larger-scale investment
• •As manufacturing scales up, the market may shift toward integrated service providers offering end-to-end solutions from design through GMP-compliant production